A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1999-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JCEM.84.11.6094PMID 10566623
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Papillary and follicular thyroid carcinoma.

  2000cited by this paper
• Cancer statistics by race and ethnicity

  1998cited by this paper
• Papillary and follicular thyroid carcinoma.

  1998cited by this paper
• IODINE KINETICS DURING I-131 SCANNING IN PATIENTS WITH THYROID CANCER: COMPARISON OF STUDIES WITH RECOMBINANT HUMAN TSH (RHTSH) VS. HYPOTHYROIDISM

  1997cited by this paper
• Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone Therapy

  1997influential reference
• Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.

  1997cited by this paper
• Follow-up of patients with thyroid carcinoma.

  1997influential reference
• Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.

  1995influential reference
• Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls.

  1995cited by this paper
• Influence of Diagnostic Radioiodines on the Uptake of Ablative Dose of Iodine-131

  1994influential reference
• Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).

  1994cited by this paper
• Long-term impact of initial and surgical therapy on papillary and follicular thyroid cancer.

  1994cited by this paper
• Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

  1994cited by this paper
• Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity.

  1993cited by this paper
• Recombinant Human Thyroid Stimulating Hormone: Development of a Biotechnology Product for Detection of Metastatic Lesions of Thyroid Carcinoma

  1993cited by this paper
• Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells.

  1991cited by this paper
• Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells.

  1991cited by this paper
• Papillary thyroid carcinoma.

  1990cited by this paper
• Natural history, treatment, and course of papillary thyroid carcinoma.

  1990cited by this paper
• Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.

  1988cited by this paper
• Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.

  1987cited by this paper
• A shortened version of the Profile of Mood States.

  1983cited by this paper
• Statistical methods applied to the diagnosis of hypothyroidism.

  1969cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Serum Thyroglobulin Autoantibodies: Prevalence, Influence on Serum Thyroglobulin Measurement, and Prognostic Significance in Patients with Differe

  year unknowncited by this paper

• Recombinant TSH Performs as Well as Thyroid Hormone Withdrawal for Iodine-131 Therapy With Dosimetry for Thyroid Cancer

  2025cites this paper
• Integrative Modeling of Thyroid Cancer Risk Prediction Using Meta Learning and Base ML Classifiers

  2025cites this paper
• RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer

  2025influential citation
• PET imaging of differentiated thyroid cancer with thyrotropin-alfa

  2025cites this paper
• Development and validation of long-acting recombinant human TSH using SAFA technology

  2025influential citation
• Pre-Treatment and Post-Treatment I-131 Imaging in Differentiated Thyroid Carcinoma

  2024cites this paper
• Diagnostic performance of 2-[18F]FDG PET/CT in recurrent differentiated thyroid cancer and elevated antithyroglobulin antibodies: an updated systematic review and bivariate meta-analysis

  2024cites this paper
• Hormone thyrostimulante

  2024cites this paper
• Recombinant or endogenous TSH for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.

  2023cites this paper
• Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.

  2023cites this paper
• A tribute to Ernest L. Mazzaferri, MD and the lasting impact that he had on thyroid cancer care ten years after his death

  2023cites this paper
• Laboratory Thyroid Tests: A Historical Perspective

  2023cites this paper
• Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma

  2023cites this paper
• A Discussion with Leonard Wartofsky, MD: Teacher, Clinician, Investigator, Mentor of Many, a Medical Politician, and Guest Editor of Thyroid Volume 1 Number 1

  2023cites this paper
• Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge

  2022cites this paper
• Effect of therapeutic radioiodine activity on ablation response in differentiated thyroid cancer patients with cut-off serum thyroglobulin levels after 2 weeks of thyroid hormone withdrawal: a retrospective study

  2022cites this paper
• Thyroglobulin Assay Interferences: Clinical Usefulness of Mass-Spectrometry Methods

  2022cites this paper
• Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer

  2022cites this paper
• Brain [18F]Fluorodeoxyglucose Metabolism Assessment under Hypothyroidism and Recombinant Human Thyroid-Stimulating Hormone in Comparison with Thyroid Hormone Replacement in Patients Submitted to Total Thyroidectomy

  2022cites this paper
• Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer—phase I/II study

  2022cites this paper
• SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.

  2022cites this paper
• Functional imaging in thyroid cancer patients with metastases and therapeutic implications.

  2022cites this paper
• Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer

  2021cites this paper
• Thyroglobulin/thyrotropin ratio for predicting long-term response in differentiated thyroid carcinoma: a retrospective study

  2021cites this paper
• Advances in Functional Imaging of Differentiated Thyroid Cancer

  2021cites this paper
• Change of Therapeutic Response Classification According to Recombinant Human Thyrotropin-Stimulated Thyroglobulin Measured at Different Time Points in Papillary Thyroid Carcinoma

  2021cites this paper
• Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma

  2021cites this paper
• Recombinant human thyroid‐stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults

  2021cites this paper
• Influence of Levothyroxine with Recombinant Human TSH on Urine Iodine Excretion Before Radioactive Iodine Administration.

  2021cites this paper
• Recombinant human thyrotropin versus thyroid hormone withdrawal in differentiated thyroid carcinoma follow-up: a single center experience.

  2021influential citation
• Quality of life comparison in thyroxine hormone withdrawal versus triiodothyronine supplementation prior to radioiodine ablation in differentiated thyroid carcinoma: a prospective cohort study in the Indian population

  2021cites this paper
• Radiation exposure to allied health personnel handling blood specimens from patients receiving radioactive iodine-131 and recombinant human TSH (thyrogen®) stimulation

  2020cites this paper
• Differentiated Thyroid Cancer: Radioiodine Therapy

  2020cites this paper
• Current practice in patients with differentiated thyroid cancer

  2020cites this paper
• A systematic review of health state utility values for thyroid cancer

  2020cites this paper
• Failure of iodine uptake in microscopic pulmonary metastases after recombinant human thyroid-stimulating hormone stimulation

  2020cites this paper
• The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer.

  2020cites this paper
• The Use of Post-ablation Stimulated Thyroglobulin in Predicting Clinical Outcomes in Differentiated Thyroid Carcinoma - What Cut-off Values Should We Use?

  2019cites this paper
• European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium

  2019cites this paper
• Surveillance for Differentiated Thyroid Cancer Recurrence.

  2019cites this paper
• Acute airway compromise after recombinant human TSH administration: A case report and review of the literature

  2019cites this paper
• Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend

  2019cites this paper
• Radioiodine Therapy of Thyroid Cancer

  2019cites this paper
• Dosimetrically determined activities in advanced differentiated thyroid carcinoma: controversies.

  2019cites this paper
• Thyroglobulin and Thyroglobulin Antibodies

  2018cites this paper
• Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH

  2018cites this paper
• Rating incidence of adverse effects after using recombinant TSH (rhTSH)

  2018cites this paper
• Chapter 2 Radioiodine Therapy of Malignant Thyroid Diseases

  2018cites this paper
• Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients

  2018cites this paper
• Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk?

  2018cites this paper
• Atlas of Thyroid and Neuroendocrine Tumor Markers

  2018influential citation
• The minimum amount of fluids needed to achieve the fastest time to reach permissible level for release in well-differentiated thyroid patients undergoing high-dose I-131 therapy

  2018cites this paper
• Pattern of urine iodine excretion with low iodine diet during preparation for radioactive iodine ablation in patients with thyroid cancer

  2018influential citation
• Usefulness of iodine-123 whole-body scan in planning iodine-131 treatment of the differentiated thyroid carcinoma in children and adolescence

  2018cites this paper
• Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer

  2017cites this paper
• Consideration of Serum Thyrotropin When Interpreting Serum Thyroglobulin Level in Patients with Differentiated Thyroid Cancer

  2017cites this paper
• Radioiodine Therapy of Malignant Thyroid Diseases

  2017cites this paper
• Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer

  2017cites this paper
• Only a Rapid Complete Biochemical Remission After 131I-Therapy is Associated with an Unimpaired Life Expectancy in Differentiated Thyroid Cancer

  2017cites this paper
• Timing of post 131 I ablation diagnostic whole body scan in differentiated thyroid cancer patients Less than four months post ablation may be too early

  2017cites this paper
• Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic 131I in the differentiated thyroid cancers

  2017cites this paper
• Surveillance Strategies After Initial Treatment of Differentiated Thyroid Cancer

  2017cites this paper
• Radioiodine Therapy.

  2017cites this paper
• Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer.

  2017cites this paper
• Erratum to: Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer

  2017cites this paper
• Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality

  2016cites this paper
• Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal.

  2016cites this paper
• Chapter 78 – Thyroid Function Testing

  2016cites this paper
• Pediatric papillary thyroid cancer: current management challenges

  2016cites this paper
• 2016 Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer

  2016cites this paper
• Pediatric papillary thyroid cancer: current management challenges

  2016cites this paper
• Recombinant human thyrotropin‐stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection

  2016cites this paper
• The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy.

  2016cites this paper
• Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer

  2016cites this paper
• Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH

  2016cites this paper
• Low iodine diet in differentiated thyroid cancer: a review

  2016cites this paper
• Patients with high‐risk differentiated thyroid cancer have a lower I‐131 ablation success rate than low‐risk ones in spite of a high ablation activity

  2016cites this paper
• Thyroid Cancer in Pediatrics.

  2016cites this paper
• Pediatric papillary thyroid cancer: current management challenges

  2016cites this paper
• Follow-Up Strategy in Papillary Thyroid Cancer

  2016cites this paper
• Recombinant Human Thyrotropin

  2016cites this paper
• Differentiated Thyroid Carcinoma with Elevated Thyroglobulin and Negative Radioiodine Whole-Body Scan Metastases

  2016cites this paper
• Radionuclide Therapy of Thyroid Tumors

  2016cites this paper
• Guidelines for Patients with Thyroid Nodules and Thyroid Cancer

  2016cites this paper
• Thyroglobulin for Differentiated Thyroid Cancer: Measurement and Interferences

  2016cites this paper
• Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries

  2016cites this paper
• Changes in Thyroid Hormone Levels Within the Normal and/or Subclinical Hyper- or Hypothyroid Range Do Not Affect Circulating Irisin Levels in Humans

  2016influential citation
• The Efficacy of Thyrotropin Suppression Therapy in Treatment of Differentiated Thyroid Cancer after Total Thyroidectomy

  2015cites this paper
• Comparison of the usefulness of post-ablative and post-operative thyroglobulin concentration measuring in prognostic assessment of patients with differentiated thyroid cancer.

  2015cites this paper
• Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients

  2015cites this paper
• Radioiodine Remnant Ablation: A Critical Review

  2015cites this paper
• Acute and Subacute, and Riedel’s Thyroiditis

  2015cites this paper
• Effect of a Low Iodine Diet vs. Restricted Iodine Diet on Postsurgical Preparation for Radioiodine Ablation Therapy in Thyroid Carcinoma Patients

  2015cites this paper
• Recombinant TSH Stimulated Remnant Ablation Therapy in Thyroid Cancer: The Success Rate Depends on the Definition of Ablation Success—An Observational Study

  2015cites this paper
• Age and body composition influence TSH concentrations after administration of rhTSH

  2015cites this paper
• Postoperative Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: An Important Imaging Modality in Patients with Aggressive Histology of Differentiated Thyroid Cancer

  2015influential citation
• The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer

  2015influential citation
• Recombinant Humanized Thyroid Stimulating Hormone (rhTSH) Preparation Prior To Radioiodine Ablation in Patients Who Have Undergone Thyroidectomy for Papillary or Follicular Thyroid Cancer

  2015cites this paper
• Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies

  2015cites this paper
• The nuclear medicine therapy care coordination service: a model for radiologist-driven patient-centered care.

  2015cites this paper